DprE1 抑制剂:对最近的发展和合成方法的洞察
Mai I Shahin1, Mai A Elyamani2, Ahmed E Elsawi3
1Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Ain Shams University, Abassia, Cairo 11566, Egypt.
概括
耐药结核病仍然是一个全球性威胁. 这项研究审查了Decaprenylphosphoryl-β-D-ribose 2'-epimerase (DprE1) 抑制剂,对于Mycobacterium结核病细胞壁合成至关重要,提供了新的抗结核治疗策略.
科学领域:
- 微生物学 微生物学
- 药用化学 医学化学
- 药物发现 药物发现 药物发现
背景情况:
- 耐药性Mycobacterium结核病 (Mtb) 是一个重大的全球卫生挑战.
- 迫切需要新的抗结核药物.
- 德卡普林酸-β-D-利酶2'-表皮酶 (DprE1) 对于mtb细胞壁的合成至关重要.
研究的目的:
- 审查与已报告的抗结核活性不同的DprE1抑制剂.
- 为了突出DprE1作为可用药物的目标的重要性.
- 提供过去15年DprE1抑制剂发展的概述.
主要方法:
- 科学出版物的文献评论. 科学出版物的文献评论.
- 报告的DprE1抑制剂及其化学支架的分析.
- 基于结合机制的抑制剂分类 (共价/非共价).
主要成果:
- DprE1 抑制剂向Mtb细胞壁生物合成中的关键酶.
- 抑制剂可以在酶的活性部位形成共价或非共价键.
- 各种化学支架已经证明了对DprE1.1的抗结核活性.
结论:
- DprE1是对抗结核病的验证和有前途的药物标.
- 目前正在探索各种化学策略,以开发新的DprE1抑制剂.
- 对DprE1抑制剂的持续研究对于解决耐药性Mtb.至关重要.
更多相关视频
10:33Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
Published on: October 26, 2015
11.3K
09:44Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
Published on: January 29, 2019
10.0K
相关概念视频
Prodrugs
2.4K
Prodrugs are a class of pharmaceutical compounds that undergo a biotransformation process within the body to be converted into a pharmacologically active drug. Prodrugs are designed to improve the therapeutic properties of the parent drug, such as enhancing bioavailability, increasing stability, or reducing toxicity. The concept of prodrugs revolves around modifying the chemical structure of the original drug to make it more effective or convenient for administration.
Prodrugs help overcome...
Prodrugs help overcome...
2.4K
Drug Discovery: Overview
7.3K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
7.3K
Structure-Activity Relationships and Drug Design
474
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
474
